Theralase Technologi (TLTFF) 0.2570 $TLTFF
Theralase Files Voluntary Annual Information Form
ACCESSWIRE - Wed Sep 24, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 24, 2014 / Theralase Technologies Inc. ("Theralase(R)"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has filed a voluntary Annual Information Form ("AIF" as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions.
Theralase Partners with Montreal's JSS Medical Research to Bring Innovative Bladder Cancer Treatment to Market
ACCESSWIRE - Thu Sep 11, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 11, 2014 / To take advantage of the vastly improved business climate in Quebec, Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it is partnering with JSS Medical Research Inc. ("JSS" , a Montreal based Contract Research Organization ("CRO" , to consult and provide guidance in the completion of a FDA / Health Canada Phase I/IIa clinical study. The clinical study planned for early 2015 will evaluate the safety and efficacy of Theralase's innovative Photo Dynamic Therapy ("PDT" platform in the destruction of bladder cancer. Theralase anticipates executing further agreements in the Quebec biotech sector worth several million dollars over the next 12 to 18 months.
Theralase Launches Multi Wavelength Laser for Cancer Destruction
ACCESSWIRE - Tue Sep 09, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / September 9, 2014 / Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds (PDCs) for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared (NIR) spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending US patent.
Theralase Releases 2Q2014 Financials
ACCESSWIRE - Fri Aug 29, 6:06AM CDT
Toronto, Ontario / ACCESSWIRE / August 29, 2014 / Theralase Technologies Inc. ("Theralase" (TLT: TSXV) (TLTFF: OTC Link) released its second quarter 2014 financial results today, demonstrating a slight increase in revenue for the three month period ended June 30, 2014, edging up 1% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.
Theralase Advances Intellectual Property of Anti-Cancer Technology
ACCESSWIRE - Thu Jul 17, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / July 17, 2014 / Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has applied for a US patent for a multi-wavelength laser light source that is capable of safely and effectively activating its patented and patent pending Photo Dynamic Compounds (PDCs) in the destruction of cancer at various tissue depths.
Theralase Grants Stock Options
ACCESSWIRE - Wed Jul 16, 6:02AM CDT
Toronto, Ontario / ACCESSWIRE / July 16, 2014 / Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Link(R)) announced effective today that it has granted an aggregate of 1,800,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue.
Theralase Technologies Treats 1 Million Patients, CEO Clip Video
Newsfile Corp - Mon Jun 30, 4:26PM CDT
full story)
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
Theralase Releases Peer-Reviewed Research on Anti-Cancer Memory Response and Destruction of Cancerous Cells
ACCESSWIRE - Tue Jun 24, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / June 24, 2014 / Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has publicly released two significant peer-reviewed research papers concerning the destruction of cancer.
Theralase Partners with University of Toledo in Cancer Research
ACCESSWIRE - Wed Jun 18, 6:03AM CDT
Toronto, Ontario / ACCESSWIRE / June 18, 2014 / Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Pink(R)) announced today that it has executed an agreement with the University of Toledo to conduct preclinical research into the safety and effectiveness of Theralase's Photo Dynamic Compounds (PDCs) in the destruction of bladder cancer in a rat model. The study is entitled, "The use of novel Photo Dynamic Therapy (PDT) in a rat bladder tumor model."
Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
Theralase Stock Upgraded on US OTC Market
ACCESSWIRE - Thu Jun 12, 6:05AM CDT
Toronto, Ontario / ACCESSWIRE / June 12, 2014 / Theralase Technologies Inc. ("Theralase" (TSXV: TLT) (TLTFF: OTC Link(R)) announced that effective June 3, 2014, its common shares, which trade in the United States Over The Counter (OTC) market under the trading symbol TLTFF, have been upgraded on a venue change from the Grey Market to the OTC Link Market.
Theralase Developing Next Generation Medical Lasers
ACCESSWIRE - Tue Mar 25, 6:13AM CDT
Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the expansion of its engineering team to develop and commercialize its next generation of smart medical laser technologies. This highly trained engineering team will be instrumental in developing Theralase products to eliminate pain and heal tissue, a $100 Billion industry in the US and to destroy cancer, a $77 Billion industry in the US.
Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Mar 12, 6:05AM CDT
Theralase Technologies Inc. (OTCBB: TLTFF) (TSX VENTURE: TLT) sells patented, superpulsed laser technology to healthcare practitioners to heal damaged tissue and eliminate pain. Theralase is also developing the next generation cancer treatment combining patented light activated compounds with laser technology to hunt down and destroy cancer.
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra...
ACCESSWIRE - Thu Feb 13, 6:01AM CST
Toronto, Ontario - February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25).
Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
ACCESSWIRE - Wed Feb 12, 9:20AM CST
2013 was a great year for Life Sciences stocks and the momentum created last year is being carried into 2014 - with a flurry of successful IPOs and financings. According to organizers at the JP Morgan Health Care Conference in January attendance was much higher than what they had anticipated and bankers were eager to do deals as more dollars flow into the space. As the wider market draws its attention to the sector the hunt for underexposed and undervalued companies is fast on. One such company is Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF); Theralase designs, develops, manufactures and markets, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. With a strong pipeline of developments leading to a Phase I clinical trial in 2015 the company looks to have a promising 2014.
Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
IIROC Trade Resumption - Theralase Technologies Inc.
Newsfile Corp - Thu Aug 29, 7:18AM CDT
Trading resumes in:
IIROC Trade Halt - Theralase Technologies Inc.
Newsfile Corp - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC:
Theralase Files Voluntary Annual Information Form
ACCESSWIRE - Wed Sep 24, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 24, 2014 / Theralase Technologies Inc. ("Theralase(R)"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has filed a voluntary Annual Information Form ("AIF" as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions. Theralase Partners with Montreal's JSS Medical Research to Bring Innovative Bladder Cancer Treatment to Market
ACCESSWIRE - Thu Sep 11, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 11, 2014 / To take advantage of the vastly improved business climate in Quebec, Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it is partnering with JSS Medical Research Inc. ("JSS" , a Montreal based Contract Research Organization ("CRO" , to consult and provide guidance in the completion of a FDA / Health Canada Phase I/IIa clinical study. The clinical study planned for early 2015 will evaluate the safety and efficacy of Theralase's innovative Photo Dynamic Therapy ("PDT" platform in the destruction of bladder cancer. Theralase anticipates executing further agreements in the Quebec biotech sector worth several million dollars over the next 12 to 18 months. Theralase Launches Multi Wavelength Laser for Cancer Destruction
ACCESSWIRE - Tue Sep 09, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / September 9, 2014 / Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds (PDCs) for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared (NIR) spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending US patent. Theralase Releases 2Q2014 Financials
ACCESSWIRE - Fri Aug 29, 6:06AM CDT
Toronto, Ontario / ACCESSWIRE / August 29, 2014 / Theralase Technologies Inc. ("Theralase"
(TLT: TSXV) (TLTFF: OTC Link) released its second quarter 2014 financial results today, demonstrating a slight increase in revenue for the three month period ended June 30, 2014, edging up 1% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies. Theralase Advances Intellectual Property of Anti-Cancer Technology
ACCESSWIRE - Thu Jul 17, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / July 17, 2014 / Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has applied for a US patent for a multi-wavelength laser light source that is capable of safely and effectively activating its patented and patent pending Photo Dynamic Compounds (PDCs) in the destruction of cancer at various tissue depths. Theralase Grants Stock Options
ACCESSWIRE - Wed Jul 16, 6:02AM CDT
Toronto, Ontario / ACCESSWIRE / July 16, 2014 / Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced effective today that it has granted an aggregate of 1,800,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue. Theralase Technologies Treats 1 Million Patients, CEO Clip Video
Newsfile Corp - Mon Jun 30, 4:26PM CDT
full story)
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
Theralase Releases Peer-Reviewed Research on Anti-Cancer Memory Response and Destruction of Cancerous Cells
ACCESSWIRE - Tue Jun 24, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / June 24, 2014 / Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has publicly released two significant peer-reviewed research papers concerning the destruction of cancer. Theralase Partners with University of Toledo in Cancer Research
ACCESSWIRE - Wed Jun 18, 6:03AM CDT
Toronto, Ontario / ACCESSWIRE / June 18, 2014 / Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Pink(R)) announced today that it has executed an agreement with the University of Toledo to conduct preclinical research into the safety and effectiveness of Theralase's Photo Dynamic Compounds (PDCs) in the destruction of bladder cancer in a rat model. The study is entitled, "The use of novel Photo Dynamic Therapy (PDT) in a rat bladder tumor model." Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
Theralase Stock Upgraded on US OTC Market
ACCESSWIRE - Thu Jun 12, 6:05AM CDT
Toronto, Ontario / ACCESSWIRE / June 12, 2014 / Theralase Technologies Inc. ("Theralase"
(TSXV: TLT) (TLTFF: OTC Link(R)) announced that effective June 3, 2014, its common shares, which trade in the United States Over The Counter (OTC) market under the trading symbol TLTFF, have been upgraded on a venue change from the Grey Market to the OTC Link Market. Theralase Developing Next Generation Medical Lasers
ACCESSWIRE - Tue Mar 25, 6:13AM CDT
Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the expansion of its engineering team to develop and commercialize its next generation of smart medical laser technologies. This highly trained engineering team will be instrumental in developing Theralase products to eliminate pain and heal tissue, a $100 Billion industry in the US and to destroy cancer, a $77 Billion industry in the US.
Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Mar 12, 6:05AM CDT
Theralase Technologies Inc. (OTCBB: TLTFF) (TSX VENTURE: TLT) sells patented, superpulsed laser technology to healthcare practitioners to heal damaged tissue and eliminate pain. Theralase is also developing the next generation cancer treatment combining patented light activated compounds with laser technology to hunt down and destroy cancer.
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra...
ACCESSWIRE - Thu Feb 13, 6:01AM CST
Toronto, Ontario - February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25).
Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
ACCESSWIRE - Wed Feb 12, 9:20AM CST
2013 was a great year for Life Sciences stocks and the momentum created last year is being carried into 2014 - with a flurry of successful IPOs and financings. According to organizers at the JP Morgan Health Care Conference in January attendance was much higher than what they had anticipated and bankers were eager to do deals as more dollars flow into the space. As the wider market draws its attention to the sector the hunt for underexposed and undervalued companies is fast on. One such company is Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF); Theralase designs, develops, manufactures and markets, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. With a strong pipeline of developments leading to a Phase I clinical trial in 2015 the company looks to have a promising 2014.
Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
IIROC Trade Resumption - Theralase Technologies Inc.
Newsfile Corp - Thu Aug 29, 7:18AM CDT
Trading resumes in:
IIROC Trade Halt - Theralase Technologies Inc.
Newsfile Corp - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC:
